Hong Kong · Delayed Price · Currency is HKD HJ Science Company Description
HJ Science Co., Ltd. engages in research and development of new small molecule drugs.
The company focuses on metabolic diseases, oncology, and autoimmune disorders. The company’s core product pipeline includes HJ787, a selective TYK2 inhibitor intended for the treatment of atopic dermatitis (AD) and acne vulgaris (AV); HJ178, an orally available agent for type 2 diabetes; and HJ891, an oral KRAS inhibitor and intravenous injection intended for the treatment of non-small-cell lung cancer (NSCLC).
It is also developing HJ197 in clinical-stage for treatment of hepatocellular carcinoma (HCC); and five preclinical drug candidates—HJ356, HJ093, HJ199, HJ198, and HJ086 for treatment of cardiovascular disease, atherosclerosis, and solid tumors.
The company was founded in 2017 and is based in Chengdu, China.
| Country | China |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Jianxin Ji |
Contact Details
Address: No. 18 N. Sec of Bayi Rd Yongning Town Chengdu China | |
| Website | hj3h.com |
Stock Details
| Ticker Symbol | 6132 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100007PD2 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jianxin Ji | Chief Executive Officer |
| Jingjie Zhang | Chief Financial Officer |
| Xiangyu Yang | Chief Operating Officer |